Invention Grant
- Patent Title: Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
-
Application No.: US16617642Application Date: 2018-05-25
-
Publication No.: US11951166B2Publication Date: 2024-04-09
- Inventor: Sabine Hoff , Lars Rose , Dieter Zopf , Fabian Kiessling , Wiltrud Lederle , Dennis Doleschel
- Applicant: BAYER AKTIENGESELLSCHAFT
- Applicant Address: DE Leverkusen
- Assignee: BAYER AKTIENGESELLSCHAFT
- Current Assignee: BAYER AKTIENGESELLSCHAFT
- Current Assignee Address: DE Leverkusen
- Agency: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
- Agent Csaba Henter
- Priority: EP 174169.7 2017.06.02
- International Application: PCT/EP2018/063785 2018.05.25
- International Announcement: WO2018/219807A 2018.12.06
- Date entered country: 2019-11-27
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K9/00 ; A61K31/44 ; A61K39/00 ; A61P35/00
Abstract:
The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
Public/Granted literature
- US20200179354A1 COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER Public/Granted day:2020-06-11
Information query
